ingentaconnect Bevacizumab costly for ovarian cancer
Links shared publicly online about this topic.
- 419total visits
ingentaconnect Bevacizumab costly for ovarian cancer
View full resource at ingentaconnect.com
Tags: Cancer, Colorectal Cancer Medication, Ovarian Cancer, Women's Health, Avastin
Most Recently Shared on March 23, 2011 at 3:08 am By:
Bevacizumab costly for ovarian cancer: (Source: PharmacoEconomics and Outcomes News)MedWorm Sponsor Message: Wat... http://bit.ly/f7ExB1
Roche's Avastin: Four More Months Of Life Worth The Cost?
medicalnewstoday.com — “Many prescription medications issued to treat potentially fatal ovarian cancer in women are quite expensive. Now in a recent study, Roche's Avastin (bevacizumab) is being called into question and” View full resource at medicalnewstoday.com
Most Recently Shared on March 10, 2011 at 6:56 am By:
Roche's Avastin: Four More Months Of Life Worth The Cost?: Many prescription medications issued to treat potent... http://bit.ly/f6R043
Roche's Avastin: Four More Months Of Life Worth The Cost?
medicalnewstoday.com — “Many prescription medications issued to treat potentially fatal ovarian cancer in women are quite expensive. Now in a recent study, Roche's Avastin (bevacizumab) is being called into question and” View full resource at medicalnewstoday.com
Most Recently Shared on March 9, 2011 at 9:05 am By:
Roche's Avastin: Four More Months Of Life Worth The Cost? http://mnt.to/3S3D #healthnews
Ovarian Cancer: Targeted Therapy Not Cost-Effective | ThirdAge
thirdage.com — “Targeted ovarian cancer therapy is not cost-effective among advanced ovarian cancer patients, an Ohio State University analysis found. For the analysis, researchers looked at 600 patients and the variety of treatment arms during one of bevacizumab--™s” View full resource at thirdage.com
Most Recently Shared on March 9, 2011 at 4:57 am By:
Ovarian Cancer: Targeted Therapy Not Cost-Effective: Targeted ovarian cancer therapy is not cost-effective among... http://bit.ly/gz9rAZ
Ohio State University Reports That Ovarian Cancer Drug Bevacizumab Is Not Cost-Effective « Libby's H*O*P*E*
healthinfoispower.wordpress.com — “Ohio State University Reports That Ovarian Cancer Drug Bevacizumab Is Not Cost-Effective « Libby's H*O*P*E*” View full resource at healthinfoispower.wordpress.com
Most Recently Shared on March 9, 2011 at 12:51 am By:
Paul Cacciatore Patient Advocate
Ohio State University Reports That Ovarian Cancer Drug Bevacizumab Is Not Cost-Effective http://wp.me/pcE2v-1tU
Targeted ovarian cancer therapy not cost-effective, study suggests
sciencedaily.com — “An analysis conducted by cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.” View full resource at sciencedaily.com
Most Recently Shared on March 9, 2011 at 12:45 am By:
Targeted ovarian cancer therapy not cost-effective, study suggests: An analysis conducted by cancer researchers ... http://bit.ly/gwRgOc
Medical News: Bevacizumab Value in Ovarian Cancer Questioned - in Clinical Context, Ovarian Cancer from MedPage Today
medpagetoday.com — “The controversial targeted agent bevacizumab (Avastin) is not cost-effective for patients with advanced ovarian cancer, researchers reported.” View full resource at medpagetoday.com
Most Recently Shared on March 8, 2011 at 10:02 pm By:
Bevacizumab Value in Ovarian Cancer Questioned (CME/CE, with video) http://bit.ly/g4wKpl
Bevacizumab Value in Ovarian Cancer Questioned (CME/CE, with video) - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- The controversial targeted agent bevacizumab (Avastin) is not cost-effective for patients with advanced ovarian cancer, researchers reported.” View full resource at qualitypointtech.net
Most Recently Shared on March 8, 2011 at 10:00 pm By:
Bevacizumab Value in Ovarian Cancer Questioned (CME/CE, with video): (MedPage Today) -- The controversial targeted... http://bit.ly/f5UiXJ
Targeted ovarian cancer therapy not cost-effective: study
physorg.com — “An analysis conducted by Ohio State University cancer researchers has found that adding the targeted therapy bevacizumab to the treatment of patients with advanced ovarian cancer is not cost effective.” View full resource at physorg.com
Most Recently Shared on March 7, 2011 at 10:00 pm By:
Targeted ovarian cancer therapy not cost-effective: study http://bit.ly/eTWomi
Advertisement
